Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

DIgital Online SuPport for COVID-19 StrEss (DISPOSE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04324190
Recruitment Status : Recruiting
First Posted : March 27, 2020
Last Update Posted : April 14, 2020
Sponsor:
Collaborator:
Selfapy GmbH
Information provided by (Responsible Party):
Gunther Meinlschmidt, International Psychoanalytic University Berlin

Brief Summary:
The COVID-19 pandemic leads to a greatly increased risk of substantial psychological stress worldwide. We intend to evaluate an online support program aiming at reducing stress in the context of the COVID-19 pandemic. The program consists of twelve modules that participants undergo, covering a broad range of topics related to stress in the context of the COVID-19 pandemic. It has been developed together with and is provided by Selfapy GmbH, Berlin. The aim of this randomised clinical trial with observational components is to estimate the effects of the intervention as a whole, as well as individual modules and selected chapters. Further, follow-up assessments as well as information on risks and the long-term course of COVID pandemic-related stress may help to elucidate COVID-19 pandemic stress across time and what we can do to prevent long-term negative consequences.

Condition or disease Intervention/treatment Phase
COVID-19 Psychosocial Stress Mental Health Behavioral: Guided online support program Behavioral: WHO recommendations (waiting condition) Not Applicable

Detailed Description:

The overall aim of this randomised trial with observational component is to estimate the effects of a guided digital online support program to increase mental health and reduce psychosocial stress in the context of the COVID-19 pandemic. More specifically, the main hypothesis is to estimate whether the improvement in mental health is stronger during the first two weeks of applying the online support program as compared to a two weeks waiting condition (with provision of WHO information on 'coping with stress during the 2019-nCoV' outbreak only). In addition to the randomised control group (second arm: waiting condition, followed by online support program), the study comprises as third arm a non-randomised comparator condition, consisting of subjects not intending to participate in the online support program. Furthermore, our aim is to estimate changes in the outcomes along taking part in the program.

Additional research questions are:

  • to compare the intervention effects across modules and chapters of the online support program, including between module comparison with an unspecific, control (comparator) module: "general information on the corona virus" and its unspecific chapters;
  • to estimate the effects of selected modules on additional outcomes (e.g. physical activity, and schooling related factors);
  • to describe the magnitude and course of psychosocial stress, mental health and related factors in the context of the COVID-19 pandemic;
  • to estimate and predict which subjects profit most from specific parts of the program.

Follow-up assessment shall include estimating whether the program prevents the development of detrimental mental health conditions, e.g. depression, anxiety, etc.

In order to make first study results available as early as possible, we intend to conduct quick complete analyses (primary outcome and relevant parts of secondary/other outcomes): These analyses will be conducted with data including subjects from the first 4 weeks of recruitment, given that a sample size of at least 300 for the online support program arm and a sample size of at least 300 for the waiting condition is reached; or if not yet reached after 4 weeks of recruitment, as soon as a sample size of at least 300 for the online support program arm and a sample size of at least 300 for the waiting condition is reached. However, we intend to continue recruiting beyond this point in time and sample size (until the COVID-19 pandemic situation has come to an end, i.e., vaccination is broadly available), to allow further, also more detailed analyses at a later point in time, resulting in more precise estimates.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 600 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Randomized controlled trial with a waiting comparator condition (provision of WHO recommendations, comparable to treatment as usual, TAU), consisting of a two weeks waiting period during which general WHO recommendations how to handle stress in the context of the COVID-19 pandemic will be provided. All subjects in the waiting condition will undergo the intervention following the waiting period. Main assessments will be conducted before the waiting period, before beginning of the intervention, two weeks after beginning of the intervention (+2 weeks), +4 weeks, +12 weeks, and follow ups at +6 months and +12 months.
Masking: Single (Care Provider)
Masking Description: Care providers (providing guidance) are not informed about wether participants have been assigned to the online support program condition or the comparator condition, consisting of a waiting period followed by the online support program.
Primary Purpose: Treatment
Official Title: Online Support for Psychosocial Stress in the Context of the COVID-19 Pandemic
Actual Study Start Date : April 8, 2020
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : December 2021

Arm Intervention/treatment
Experimental: Online support program
Guided online support program, consisting of modules (structured in chapters) aiming at reduce stress related to the COVID-19 pandemic.
Behavioral: Guided online support program
Guided online support program consisting of several modules; Module "General information ..." is an unspecific control module (providing general information on hygiene etc. with no expected effect on outcomes)
Other Names:
  • online intervention
  • guided online support

Active Comparator: Waiting period (WHO recommendation)
Waiting period (2 weeks duration) during which subjects are provided with the WHO recommendations "Coping with stress during the 2019 nCoV outbreak". Following the 2 weeks waiting period, subjects are provided with the guided online support program outlined in the arm 'online support program'.
Behavioral: Guided online support program
Guided online support program consisting of several modules; Module "General information ..." is an unspecific control module (providing general information on hygiene etc. with no expected effect on outcomes)
Other Names:
  • online intervention
  • guided online support

Behavioral: WHO recommendations (waiting condition)
During the waiting period, a german translation of the WHO recommendations "Coping with stress during the 2019-nCoV outbreak" is provided

No Intervention: No intervention (natural course)
This non-randomised arm (recruited separately; anticipated sample size of 500 subjects, not counted in the overall anticipated sample size) consists of subjects not intending to participate in the Selfapy online support program. Assessment points in this arm are comparable to those in the arm "Online support program" (in the 'No intervention (natural course)' arm, T1 refers to time of study inclusion).



Primary Outcome Measures :
  1. Change in Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score [ Time Frame: Change from T1 (baseline before online support - day 1) to T2 (T1 + 2 weeks) in arm 1, versus change from T0 (baseline before waiting) to T1 (baseline before online support) in arm 2 ]
    The SF-36 is a widely used patient-reported outcome assessment tool to measure health-related quality of life and has high acceptability. The SF-36 is a standardised questionnaire with good psychometric properties.


Secondary Outcome Measures :
  1. Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score [ Time Frame: T2 (T1+2 weeks) (arm 2 only), T3 (T1+4 weeks), T4 (T1+12 weeks), follow ups: T1+ 6 months, T1+12 months ]
    mental health related quality of life

  2. Chronic stress items (9 items) [ Time Frame: baseline before waiting (T0, arm 2 only); baseline before online support (day 1, T1), T2 (T1+2 weeks), T3 (T1+4 weeks), T4 (T1+12 weeks), follow ups: T1+ 6 months, T1+12 months ]
    Assessing chronic stress (Petrowski et al., 2019)

  3. Generalized Anxiety Disorder Scale (GAD-7) [ Time Frame: baseline before waiting (T0, arm 2 only); baseline before online support (day 1, T1), T2 (T1+2 weeks), T3 (T1+4 weeks), T4 (T1+12 weeks), follow ups: T1+ 6 months, T1+12 months ]
    Assessing anxiety symptoms (Löwe et al., 2008)

  4. Patient Health Questionnaire (PHQ8) [ Time Frame: baseline before waiting (T0, arm 2 only); baseline before online support (day 1, T1), T2 (T1+2 weeks), T3 (T1+4 weeks), T4 (T1+12 weeks), follow ups: T1+ 6 months, T1+12 months ]
    Assessing depressive symptoms (Kroenke et al., 2001)

  5. Somatic Symptom Disorder (SSD-12) [ Time Frame: baseline before waiting (T0, arm 2 only); baseline before online support (day 1, T1), T2 (T1+2 weeks), T3 (T1+4 weeks), T4 (T1+12 weeks), follow ups: T1+ 6 months, T1+12 months ]
    Assessing depressive symptoms (Toussaint et al., 2019)

  6. Somatic Symptom Scale (SSS-8) [ Time Frame: baseline before waiting (T0, arm 2 only); baseline before online support (day 1, T1), T2 (T1+2 weeks), T3 (T1+4 weeks), T4 (T1+12 weeks), follow ups: T1+ 6 months, T1+12 months ]
    Assessing somatic symptoms (Gierk et al., 2015)

  7. Allgemeine Selbstwirksamkeit Kurzskala (ASKU) [ Time Frame: baseline before waiting (T0, arm 2 only); baseline before online support (day 1, T1), T2 (T1+2 weeks), T3 (T1+4 weeks), T4 (T1+12 weeks), follow ups: T1+ 6 months, T1+12 months ]
    competence expectations to deal with difficulties and obstacles in daily life (Beierlein et al., 2014)

  8. Screening Tool for Psychological Distress (STOP-D) - selected items [ Time Frame: baseline before waiting (T0, arm 2 only); baseline before online support (day 1, T1), T1+2 weeks, T1+4 weeks, T1+12 weeks, follow ups: T1+ 6 months, T1+12 months; before & after each module of the online intervention ]
    stress, anxiety, depression, social support - single item assessments to be applied repeatedly along the online support intervention (Young, Ignaszewski, Fofonoff, Kaan; 2007), including stress of children and anticipation


Other Outcome Measures:
  1. Physical activity [ Time Frame: baseline before waiting (T0, arm 2 only); baseline before online support (day 1, T1), T1+2 weeks, T1+4 weeks, T1+12 weeks, follow ups: T1+ 6 months, T1+12 months; before & after sports and physical activity module; at baseline: before COVID-19 pandemic ]
    Vigorous, moderate, and walking activity (minutes/day)

  2. Home-schooling [ Time Frame: baseline before waiting (T0, arm 2 only); baseline before online support (day 1, T1), T1+2 weeks, T1+4 weeks, T1+12 weeks, follow ups: T1+ 6 months, T1+12 months; before & after sports and physical activity module; at baseline: before COVID-19 pandemic ]
    Questions related to home-schooling related stress & learning

  3. Information related to COVID-19 and SARS-CoV-2 [ Time Frame: baseline before waiting (T0, arm 2 only); baseline before online support (day 1, T1), T1+2 weeks, T1+4 weeks, T1+12 weeks, follow ups: T1+ 6 months, T1+12 months; before & after the sports and physical activity module of the online intervention ]
    Questions related to COVID-19 and SARS-CoV-2 symptoms, disease, and testing, anxiety, stressors

  4. Unintended effects [ Time Frame: only after undergoing online support program: T1+2 weeks, T1+4 weeks, T1+12 weeks, follow ups: T1+ 6 months, T1+12 months ]
    Unintended effects of online support program



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria, general:

  • Sufficient German language skills to participate in the assessments.
  • Providing informed consent for participation.

Inclusion criteria for the arms "Online support program" and "Waiting condition...":

- Having signed up for the online support program provided by selfapy GmbH, Berlin, Germany (www.selfapy.de/corona) aiming at reducing burden in the context of the COVID-19 pandemic.

Inclusion criteria for the arm "No intervention...":

- Not having signed up for the online support program provided by selfapy GmbH, Berlin, Germany (www.selfapy.de/corona) aiming at reducing burden in the context of the COVID-19 pandemic.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04324190


Contacts
Layout table for location contacts
Contact: Gunther Meinlschmidt, Prof. Dr. +49 30 300117 ext 710 gunther.meinlschmidt@ipu-berlin.de

Locations
Layout table for location information
Germany
Selfapy GmbH Recruiting
Berlin, Germany, 10435
Contact: Kati Bermbach    +49 (0) 30 - 3982031 ext 20    contact@selfapy.com   
Sponsors and Collaborators
Gunther Meinlschmidt
Selfapy GmbH
Layout table for additonal information
Responsible Party: Gunther Meinlschmidt, Prof. Dr., International Psychoanalytic University Berlin
ClinicalTrials.gov Identifier: NCT04324190    
Other Study ID Numbers: IPUB_2020_01
First Posted: March 27, 2020    Key Record Dates
Last Update Posted: April 14, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Gunther Meinlschmidt, International Psychoanalytic University Berlin:
COVID-19
SARS-CoV-2
psychosocial stress
online support
guided
mental health
anxiety
depression
somatic symptom disorder